ArticleProceedings (Baylor University. Medical Center)2018
Efficacy and safety of transarterial chemoembolization with 70- to 150-μm drug-eluting beads alone or in combination with 100- to 300-μm drug-eluting beads.
Article in Proceedings (Baylor University. Medical Center), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the safety and efficacy of transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma, a retrospective analysis of patients who underwent TACE utilizing up to one vial of LC BeadM1 (70-150 μm) embolics with doxorubicin was performed. If tumor devascularization was not achieved, up to one additional vial of LC Bead (100-300 μm) embolics with doxorubicin was subsequently administered. Ninety-four sessions of TACE were completed among 48 patients. After a mean follow-up of 182 days, complete response was achieved in 10 patients (21%), partial response in 19 (40%), stable disease in 8 (17%), and progressive disease in 10 (21%). Disease control was achieved in 79% of patients: 90% of patients treated with 70- to 150-μm embolics alone vs. 70% of patients treated with both sizes of embolics (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.